Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges
NVONovo Nordisk(NVO) MarketBeat·2024-09-24 21:54

Novo Nordisk A/S TodayNVONovo Nordisk A/S$124.61 +0.91 (+0.74%) 52-Week Range$86.96▼$148.15Dividend Yield0.58%P/E Ratio42.97Price Target$145.17Add to WatchlistNovo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result. This included firms like Eli Lilly NYSE: LLY and Structure Therapeutics NASDAQ: GPCR.The drug in question was monlunabant. Although not a GLP-1 tre ...